Cascade-Enhanced Chemodynamic Therapy via a Mitochondria-Targeted PEI-Fc-Gox Nanogel with Dual Antihypoxia and ROS
Shuhao Wang1, Zhengwei Yan1, Zongze Duan1
1Key Laboratory of Hubei Province for Coal Conversion and New Carbon Materials, School of Chemistry and Chemical Engineering, Wuhan University of Science and Technology, Wuhan430081, China.
None:
The glucose oxidase (GOx)-catalyzed oxidation of glucose generates an acidic microenvironment and supplies H2O2 as the essential substrate for intracellular Fenton reactions. However, the efficiency of this process is often constrained by the hypoxic conditions in tumor tissues. To address this limitation, we developed a mitochondria-targeted PFAGD nanogel, by covalently conjugating ferrocene (Fc) and GOx onto a polyethylenimine (PEI) backbone and encapsulating atovaquone (ATO), a mitochondrial respiration inhibitor. Surface modification with DNA-TPP enabled mitochondrial targeting. The incorporated ATO effectively alleviated intracellular hypoxia, thereby promoting the GOx/Fc-mediated cascaded Fenton reaction. This process drove substantial ROS (particularly ·OH) generation, thereby amplifying chemodynamic therapy. Multiple cellular assays confirmed that the three-step cascade reaction in the PFAGD nanogel enhanced the proliferation inhibition effect on cancer cells, especially under hypoxic conditions. This self-reinforcing nanoplatform mitigates tumor hypoxia and enables sustained, localized ROS generation, offering a promising strategy for catalytic anticancer therapy.
Related Concept Videos
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...


